Products – LumiThera

Light-Based Scientific Innovations

Our innovations drive the advancement of vision preservation and improvement. We focus on early detection, intervention, and comprehensive degenerative disease monitoring. Our first area of focus is dry age-related macular degeneration (AMD)

Valeda® Light Delivery System

Valeda is the first and only FDA-authorized treatment for dry age-related macular degeneration (AMD) to improve vision

Valeda photobiomodulation (PBM) treatment is non-invasive and targets disease at the cellular level. Valeda delivers select wavelengths of light that act on cellular mechanisms important to dry AMD and enhance mitochondrial function to improve cellular energy (ATP) production.

Unlike high-power lasers used for surgery, PBM involves low-intensity light that does not cause heat or damage, making it a safe and effective treatment option for ocular diseases such as dry AMD.

PBM has applications and is being studied across various fields, including dermatology, neurology, and ophthalmology, for conditions such as wound healing, neurodegenerative diseases, and macular degeneration.

Valeda is available in the US, EU, and UK, as well as select countries in Central and South America.

MyValeda.com »

Valeda Indications for Use

U.S. Indications for Use

The Valeda Light Delivery System is intended to provide improved visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by:

The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, AND The absence of neovascular maculopathy or central-involving geographic atrophy After about two years, the Valeda Light Delivery System treatment provides improved mean visual acuity of approximately one line of visual acuity (ETDRS) compared to those not receiving the treatment.

Indications for Use outside the U.S.*

The indicated use is for treatment of ocular damage and disease using photobiomodulation, including inhibition of inflammatory mediators, edema or drusen deposition, improvement of wound healing following ocular trauma or surgery, and increase in visual acuity and contrast sensitivity in patients with degenerative diseases such as dry age-related macular degeneration.

*Indications for use determined by region. Contact LumiThera for more information.

Valeda Contraindications for Use

As a precaution, patients have not been tested and should not be treated with Valeda if they have any known photosensitivity to yellow light, red light, or near-infrared radiation (NIR), or if they have a history of light-activated central nervous system disorders (e.g., epilepsy, migraine). In addition, patients should not receive treatment within 30 days of using photosensitizing agents (e.g., topicals, injectables) that are affected by 590, 660, and/or 850 nm light before consulting with their physician.

Refer to the Valeda User Manual for full Important Safety Information.